Myriad Genetics to Announce Financial Results for the Fiscal Fourth Quarter and Full Year 2014 on August 12, 2014
July 30 2014 - 12:00PM
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will
issue financial results for the fiscal fourth quarter and full year
2014 as well as provide financial guidance for fiscal year 2015
following the close of market on Tuesday, August 12, 2014.
The Company also will host a conference call at 4:30 p.m. ET on
August 12, 2014 to discuss the financial results. Participating on
the call will be Peter Meldrum, president and CEO; Mark Capone,
president of Myriad Genetic Laboratories, Inc., and James Evans,
chief financial officer.
To listen to the call, interested parties in the United States
may dial 800-707-7427 or +1 416-352-0001 for international
callers. All callers will be asked to reference reservation
number 21728148.
The conference call also will be available through a live
webcast at www.myriad.com. A replay of the call will be available
two hours after the end of the call for seven days and may be
accessed by dialing 800-633-8284 within the United States or +1
402-977-9140 for international callers and entering reservation
number 21728148.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad's
molecular diagnostic tests are based on an understanding of the
role genes play in human disease and were developed with a
commitment to improving an individual's decision making process for
monitoring and treating disease. Myriad is focused on strategic
directives to introduce new products, including companion
diagnostics, as well as expanding internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo and Myriad myRisk Hereditary Cancer, are
trademarks or registered trademarks of Myriad Genetics, Inc. in the
United States and foreign countries. MYGN-F, MYGN-G.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024